Evolus Inc (NASDAQ:EOLS) saw unusually large options trading on Thursday. Stock traders acquired 2,135 call options on the company. This is an increase of approximately 1,343% compared to the average volume of 148 call options.
A number of equities analysts have weighed in on EOLS shares. HC Wainwright reissued a “buy” rating and set a $37.00 price objective on shares of Evolus in a research note on Thursday, April 4th. Zacks Investment Research lowered Evolus from a “hold” rating to a “sell” rating in a research note on Wednesday, January 23rd. Stifel Nicolaus started coverage on Evolus in a research note on Monday, January 28th. They set a “buy” rating and a $27.00 price objective on the stock. SunTrust Banks started coverage on Evolus in a research note on Wednesday, March 20th. They set a “buy” rating and a $30.00 price objective on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Evolus in a research note on Tuesday, March 19th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Evolus has a consensus rating of “Buy” and an average price target of $30.71.
Institutional investors have recently made changes to their positions in the company. BlackRock Inc. lifted its stake in shares of Evolus by 104.9% in the 3rd quarter. BlackRock Inc. now owns 615,719 shares of the company’s stock valued at $11,465,000 after purchasing an additional 315,210 shares during the last quarter. Inverness Counsel LLC NY acquired a new position in shares of Evolus in the 4th quarter valued at $190,000. Citigroup Inc. lifted its stake in shares of Evolus by 4,361.6% in the 4th quarter. Citigroup Inc. now owns 24,851 shares of the company’s stock valued at $296,000 after purchasing an additional 24,294 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Evolus by 32.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 20,367 shares of the company’s stock valued at $379,000 after purchasing an additional 5,005 shares during the last quarter. Finally, Chartwell Investment Partners LLC acquired a new position in shares of Evolus in the 4th quarter valued at $903,000. 19.33% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ EOLS opened at $16.10 on Friday. Evolus has a fifty-two week low of $10.22 and a fifty-two week high of $39.50. The firm has a market cap of $440.06 million, a price-to-earnings ratio of -10.25 and a beta of 5.01. The company has a current ratio of 14.80, a quick ratio of 14.52 and a debt-to-equity ratio of 0.96.
Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Tuesday, April 30th. The company reported ($0.93) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by ($0.11). Equities analysts anticipate that Evolus will post -3.06 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://transcriptdaily.com/2019/05/18/evolus-sees-unusually-large-options-volume-eols.html.
Evolus Company Profile
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Article: What are popular range trading strategies?
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.